Base de dados : MEDLINE
Pesquisa : D12.776.828.868 [Categoria DeCS]
Referências encontradas : 11534 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1154 ir para página                         

  1 / 11534 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460340
[Au] Autor:Medaglini D; Siegrist CA
[Ad] Endereço:Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
[Ti] Título:Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine.
[So] Source:Curr Opin Virol;23:88-94, 2017 04.
[Is] ISSN:1879-6265
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The rVSV-ZEBOV vaccine is currently the only Ebola vaccine with demonstrated clinical efficacy in a ring-vaccination clinical trial. It has been shown to be reactogenic but immunogenic and safe in several Phase I clinical studies. However, its mechanisms of protection are unknown and available immunogenicity data are mostly limited to classical serological analysis; it is now of paramount importance to apply cutting-edge technologies, including transcriptomic and metabolomic analyses, and to perform integrative analyses with standard serology and clinical data to comprehensively profile the rVSV-ZEBOV immune signature.
[Mh] Termos MeSH primário: Vacinas contra Ebola/imunologia
Ebolavirus/imunologia
Doença pelo Vírus Ebola/prevenção & controle
[Mh] Termos MeSH secundário: Portadores de Fármacos
Vacinas contra Ebola/administração & dosagem
Perfilação da Expressão Gênica
Seres Humanos
Imunoensaio
Metaboloma
Vacinas Sintéticas/administração & dosagem
Vacinas Sintéticas/imunologia
Vesiculovirus/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Drug Carriers); 0 (Ebola Vaccines); 0 (Vaccines, Synthetic)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  2 / 11534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464937
[Au] Autor:Greenwood B; Dicko A; Sagara I; Zongo I; Tinto H; Cairns M; Kuepfer I; Milligan P; Ouedraogo JB; Doumbo O; Chandramohan D
[Ad] Endereço:Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel St., London, WC1E 7HT, UK. brian.greenwood@lshtm.ac.uk.
[Ti] Título:Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine.
[So] Source:Malar J;16(1):182, 2017 05 02.
[Is] ISSN:1475-2875
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In many parts of the African Sahel and sub-Sahel, where malaria remains a major cause of mortality and morbidity, transmission of the infection is highly seasonal. Seasonal malaria chemoprevention (SMC), which involves administration of a full course of malaria treatment to young children at monthly intervals during the high transmission season, is proving to be an effective malaria control measure in these areas. However, SMC does not provide complete protection and it is demanding to deliver for both families and healthcare givers. Furthermore, there is a risk of the emergence in the future of resistance to the drugs, sulfadoxine-pyrimethamine and amodiaquine, that are currently being used for SMC. Substantial progress has been made in the development of malaria vaccines during the past decade and one malaria vaccine, RTS,S/AS01, has received a positive opinion from the European Medicines Authority and will soon be deployed in large-scale, pilot implementation projects in sub-Saharan Africa. A characteristic feature of this vaccine, and potentially of some of the other malaria vaccines under development, is that they provide a high level of efficacy during the period immediately after vaccination, but that this wanes rapidly, perhaps because it is difficult to develop effective immunological memory to malaria antigens in subjects exposed previously to malaria infection. A potentially effective way of using malaria vaccines with high initial efficacy but which provide only a short period of protection could be annual, mass vaccination campaigns shortly before each malaria transmission season in areas where malaria transmission is confined largely to a few months of the year.
[Mh] Termos MeSH primário: Vacinas Antimaláricas/administração & dosagem
Vacinas Antimaláricas/imunologia
Malária/prevenção & controle
Estações do Ano
Vacinação/utilização
Vacinas Sintéticas/administração & dosagem
Vacinas Sintéticas/imunologia
[Mh] Termos MeSH secundário: África ao Sul do Saara
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Malaria Vaccines); 0 (RTS,S-AS01 vaccine); 0 (Vaccines, Synthetic)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s12936-017-1841-9


  3 / 11534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29370152
[Au] Autor:Dooling KL; Guo A; Patel M; Lee GM; Moore K; Belongia EA; Harpaz R
[Ti] Título:Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.
[So] Source:MMWR Morb Mortal Wkly Rep;67(3):103-108, 2018 Jan 26.
[Is] ISSN:1545-861X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit vaccine containing recombinant glycoprotein E in combination with a novel adjuvant (AS01 ), was approved by the Food and Drug Administration for the prevention of herpes zoster in adults aged ≥50 years. The vaccine consists of 2 doses (0.5 mL each), administered intramuscularly, 2-6 months apart (1). On October 25, 2017, the Advisory Committee on Immunization Practices (ACIP) recommended the recombinant zoster vaccine (RZV) for use in immunocompetent adults aged ≥50 years.
[Mh] Termos MeSH primário: Vacina contra Herpes Zoster/administração & dosagem
Herpes Zoster/prevenção & controle
Guias de Prática Clínica como Assunto
[Mh] Termos MeSH secundário: Comitês Consultivos
Idoso
Seres Humanos
Esquemas de Imunização
Imunocompetência
Meia-Idade
Estados Unidos
United States Food and Drug Administration
Vacinas Atenuadas/administração & dosagem
Vacinas Sintéticas/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Herpes Zoster Vaccine); 0 (Vaccines, Attenuated); 0 (Vaccines, Synthetic)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.15585/mmwr.mm6703a5


  4 / 11534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29351298
[Au] Autor:Noyce RS; Lederman S; Evans DH
[Ad] Endereço:Department of Medical Microbiology & Immunology and Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.
[Ti] Título:Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments.
[So] Source:PLoS One;13(1):e0188453, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Edward Jenner and his contemporaries believed that his variolae vaccinae originated in horses and molecular analyses show that modern vaccinia virus (VACV) strains share common ancestry with horsepox virus (HPXV). Given concerns relating to the toxicity of modern VACV vaccines, we asked whether an HPXV-based vaccine might provide a superior alternative. Since HPXV may be extinct and the only specimen of HPXV that has been identified is unavailable for investigation, we explored whether HPXV could be obtained by large-scale gene synthesis. Ten large (10-30 kb) fragments of DNA were synthesized based on the HPXV sequence along with two 157 nt VACV terminal sequences, and were recombined into a live synthetic chimeric HPXV (scHPXV) in cells infected with Shope fibroma virus (SFV). Sequencing of the 212 kbp scHPXV confirmed it encoded a faithful copy of the input DNA. We believe this is the first complete synthesis of a poxvirus using synthetic biology approaches. This scHPXV produced smaller plaques, produced less extracellular virus and exhibited less virulence in mice than VACV, but still provided vaccine protection against a lethal VACV challenge. Collectively, these findings support further development of scHPXV as a novel replication-proficient smallpox vaccine.
[Mh] Termos MeSH primário: DNA/química
Orthopoxvirus/imunologia
Vacinas Sintéticas/imunologia
Vacinas Virais/imunologia
[Mh] Termos MeSH secundário: Administração Intranasal
Animais
Cercopithecus aethiops
Células HeLa
Seres Humanos
Camundongos
Orthopoxvirus/crescimento & desenvolvimento
Orthopoxvirus/patogenicidade
Vacinas Sintéticas/administração & dosagem
Células Vero
Vacinas Virais/administração & dosagem
Virulência
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Vaccines, Synthetic); 0 (Viral Vaccines); 9007-49-2 (DNA)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180120
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0188453


  5 / 11534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29309783
[Au] Autor:Picchio MS; Sánchez VR; Arcon N; Soto AS; Perrone Sibilia M; Aldirico MLA; Urrutia M; Moretta R; Fenoy IM; Goldman A; Martin V
[Ad] Endereço:Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, Escuela de Ciencia y Tecnología, Universidad Nacional de San Martín, Campus Migueletes, Martín de Irigoyen 3100 C.P., 1650 San Martín, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290
[Ti] Título:Vaccine potential of antigen cocktails composed of recombinant Toxoplasma gondii TgPI-1, ROP2 and GRA4 proteins against chronic toxoplasmosis in C3H mice.
[So] Source:Exp Parasitol;185:62-70, 2018 Feb.
[Is] ISSN:1090-2449
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The development of an effective and safe vaccine to prevent Toxoplasma gondii infection is an important aim due to the great clinical and economic impact of this parasitosis. We have previously demonstrated that immunization with the serine protease inhibitor-1 (TgPI-1) confers partial protection to C3H/HeN and C57BL/6 mice. In order to improve the level of protection, in this work, we combined this novel antigen with ROP2 and/or GRA4 recombinant proteins (rTgPI-1+rROP2, rTgPI-1+rGRA4, rTgPI-1+rROP2+rGRA4) to explore the best combination against chronic toxoplasmosis in C3H/HeN mice. All tested vaccine formulations, administered following a homologous prime-boost protocol that combines intradermal and intranasal routes, conferred partial protection as measured by the reduction of brain cyst burden following oral challenge with tissue cysts of Me49 T. gondii strain. The highest level of protection was achieved by the mixture of rTgPI-1 and rROP2 proteins with an average parasite burden reduction of 50% compared to the unvaccinated control group. The vaccine-induced protective effect was related to the elicitation of systemic cellular and humoral immune responses that included antigen-specific spleen cell proliferation, the release of Th1/Th2 cytokines, and the generation of antigen-specific antibodies in serum. Additionally, mucosal immune responses were also induced, characterized by secretion of antigen-specific IgA antibodies in intestinal lavages and specific mesenteric lymph node cell proliferation. Our results demonstrate that rTgPI-1+rROP2 antigens seem a promising mixture to be combined with other immunogenic proteins in a multiantigenic vaccine formulation against toxoplasmosis.
[Mh] Termos MeSH primário: Antígenos de Protozoários/imunologia
Vacinas Protozoárias/normas
Toxoplasma/imunologia
Toxoplasmose Animal/prevenção & controle
[Mh] Termos MeSH secundário: Animais
Anticorpos Antiprotozoários/sangue
Linhagem Celular
Doença Crônica
Citocinas/metabolismo
Feminino
Fibroblastos/parasitologia
Prepúcio do Pênis/citologia
Seres Humanos
Imunoglobulina A Secretora/análise
Imunoglobulina G/sangue
Mucosa Intestinal/imunologia
Masculino
Proteínas de Membrana/imunologia
Camundongos
Camundongos Endogâmicos C3H
Proteínas de Protozoários/imunologia
Baço/citologia
Baço/imunologia
Vacinas Sintéticas/normas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Protozoan); 0 (Antigens, Protozoan); 0 (Cytokines); 0 (GRA4 protein, Toxoplasma gondii); 0 (Immunoglobulin A, Secretory); 0 (Immunoglobulin G); 0 (Membrane Proteins); 0 (Protozoan Proteins); 0 (Protozoan Vaccines); 0 (ROP 2 protein, Toxoplasma gondii); 0 (TgPI protein, Toxoplasma gondii); 0 (Vaccines, Synthetic)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180109
[St] Status:MEDLINE


  6 / 11534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28989096
[Au] Autor:Wussow F; Chiuppesi F; Meng Z; Martinez J; Nguyen J; Barry PA; Diamond DJ
[Ad] Endereço:Department of Experimental Therapeutics, Beckman Research Institute of the City of Hope, Duarte, CA, USA. Electronic address: fwussow@coh.org.
[Ti] Título:Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex.
[So] Source:J Virol Methods;251:30-37, 2018 Jan.
[Is] ISSN:1879-0984
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Neutralizing antibodies (NAb) interfering with glycoprotein complex-mediated virus entry into host cells are thought to contribute to the protection against herpesvirus infection. However, using herpesvirus glycoprotein complexes as vaccine antigens can be complicated by the necessity of expressing multiple subunits simultaneously to allow efficient complex assembly and formation of conformational NAb epitopes. By using a novel bacterial artificial chromosome (BAC) clone of the clinically deployable Modified Vaccinia Ankara (MVA) vector and exploiting ribosomal skipping mediated by 2A peptides, MVA vectors were generated that expressed self-processing subunits of the human cytomegalovirus (HCMV) pentamer complex (PC) composed of gH, gL, UL128, UL130, and UL131A. These MVA vectors expressed 2A-linked HCMV PC subunits that were efficiently cleaved and transported to the cell surface as protein complexes forming conformational neutralizing epitopes. In addition, vaccination of mice by only two immunizations with these MVA vectors resulted in potent HCMV NAb responses that remained stable over a period of at least six months. This method of eliciting NAb by 2A-linked, self-processing HCMV PC subunits could contribute to develop a HCMV vaccine candidate and may serve as a template to facilitate the development of subunit vaccine strategies against other herpesviruses.
[Mh] Termos MeSH primário: Anticorpos Neutralizantes/sangue
Anticorpos Antivirais/sangue
Antígenos Virais/imunologia
Vacinas contra Citomegalovirus/imunologia
Citomegalovirus/imunologia
Glicoproteínas/imunologia
Proteínas Estruturais Virais/imunologia
[Mh] Termos MeSH secundário: Animais
Antígenos Virais/genética
Citomegalovirus/genética
Vacinas contra Citomegalovirus/administração & dosagem
Vacinas contra Citomegalovirus/genética
Vetores Genéticos
Glicoproteínas/genética
Esquemas de Imunização
Camundongos
Vacinas Sintéticas/administração & dosagem
Vacinas Sintéticas/genética
Vacinas Sintéticas/imunologia
Vírus Vaccinia/genética
Proteínas Estruturais Virais/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Antigens, Viral); 0 (Cytomegalovirus Vaccines); 0 (Glycoproteins); 0 (Vaccines, Synthetic); 0 (Viral Structural Proteins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171010
[St] Status:MEDLINE


  7 / 11534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28987424
[Au] Autor:Barbieri A; Panigada M; Soprana E; Di Mario G; Gubinelli F; Bernasconi V; Recagni M; Donatelli I; Castrucci MR; Siccardi AG
[Ad] Endereço:Molecular Immunology Unit, San Raffaele Research Institute, Via Olgettina 58, 20132, Milan, Italy; Department of Medical Biotechnology and Translational Medicine, University of Milan, Via Vanvitelli, 32, 20129, Milan, Italy.
[Ti] Título:Strategies to obtain multiple recombinant modified vaccinia Ankara vectors. Applications to influenza vaccines.
[So] Source:J Virol Methods;251:7-14, 2018 Jan.
[Is] ISSN:1879-0984
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:As a vaccination vector, MVA has been widely investigated both in animal models and humans. The construction of recombinant MVA (rMVA) relies on homologous recombination between an acceptor virus and a donor plasmid in infected/transfected permissive cells. Our construction strategy "Red-to-Green gene swapping" - based on the exchange of two fluorescent markers within the flanking regions of MVA deletion ΔIII, coupled to fluorescence activated cell sorting - is here extended to a second insertion site, within the flanking regions of MVA deletion ΔVI. Exploiting this strategy, both double and triple rMVA were constructed, expressing as transgenes the influenza A proteins HA, NP, M1, and PB1. Upon validation of the harbored transgenes co-expression, double and triple recombinants rMVA(ΔIII)-NP-P2A-M1 and rMVA(ΔIII)-NP-P2A-M1-(ΔVI)-PB1 were assayed for in vivo immunogenicity and protection against lethal challenge. In vivo responses were identical to those obtained with the reported combinations of single recombinants, supporting the feasibility and reliability of the present improvement and the extension of Red-to-Green gene swapping to insertion sites other than ΔIII.
[Mh] Termos MeSH primário: Portadores de Fármacos
Vetores Genéticos
Vacinas contra Influenza/imunologia
Vírus Vaccinia/genética
[Mh] Termos MeSH secundário: Animais
Anticorpos Antivirais/sangue
Antígenos Virais/genética
Antígenos Virais/imunologia
Linfócitos T CD8-Positivos/imunologia
Expressão Gênica
Vacinas contra Influenza/administração & dosagem
Vacinas contra Influenza/genética
Camundongos Endogâmicos C57BL
Proteínas Recombinantes/genética
Proteínas Recombinantes/imunologia
Análise de Sobrevida
Vacinas Sintéticas/administração & dosagem
Vacinas Sintéticas/genética
Vacinas Sintéticas/imunologia
Proteínas Virais/genética
Proteínas Virais/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Antigens, Viral); 0 (Drug Carriers); 0 (Influenza Vaccines); 0 (Recombinant Proteins); 0 (Vaccines, Synthetic); 0 (Viral Proteins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171009
[St] Status:MEDLINE


  8 / 11534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Texto completo
[PMID]:28464026
[Au] Autor:Diemert DJ; Freire J; Valente V; Fraga CG; Talles F; Grahek S; Campbell D; Jariwala A; Periago MV; Enk M; Gazzinelli MF; Bottazzi ME; Hamilton R; Brelsford J; Yakovleva A; Li G; Peng J; Correa-Oliveira R; Hotez P; Bethony J
[Ad] Endereço:Department of Microbiology, Immunology and Tropical Medicine, School of Medicine and Health Sciences, The George Washington University, Washington DC, United States of America.
[Ti] Título:Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults.
[So] Source:PLoS Negl Trop Dis;11(5):e0005574, 2017 05.
[Is] ISSN:1935-2735
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Necator americanus Glutathione-S-Transferase-1 (Na-GST-1) plays a role in the digestion of host hemoglobin by adult N. americanus hookworms. Vaccination of laboratory animals with recombinant Na-GST-1 is associated with significant protection from challenge infection. Recombinant Na-GST-1 was expressed in Pichia pastoris and adsorbed to aluminum hydroxide adjuvant (Alhydrogel) according to current Good Manufacturing Practice. Two Phase 1 trials were conducted in 142 healthy adult volunteers in the United States and Brazil, first in hookworm-naïve individuals and then in residents of a N. americanus endemic area in Brazil. Volunteers received one of three doses of recombinant Na-GST-1 (10, 30, or 100 µg) adjuvanted with Alhydrogel, adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl Lipid A (GLA-AF), or the hepatitis B vaccine. Vaccinations were administered via intramuscular injection on days 0, 56, and 112. Na-GST-1/Alhydrogel was well tolerated in both hookworm-naïve and hookworm-exposed adults, with the most common adverse events being mild to moderate injection site pain and tenderness, and mild headache and nausea; no vaccine-related severe or serious adverse events were observed. Antigen-specific IgG antibodies were induced in a dose-dependent fashion, with increasing levels observed after each vaccination in both trials. The addition of GLA-AF to Na-GST-1/Alhydrogel did not result in significant increases in specific IgG responses. In both the US and Brazil studies, the predominant IgG subclass induced against Na-GST-1 was IgG1, with lesser amounts of IgG3. Vaccination of both hookworm-naïve and hookworm-exposed adults with recombinant Na-GST-1 was safe, well tolerated, and resulted in significant antigen-specific IgG responses. Based on these results, this vaccine will be advanced into clinical trials in children and eventual efficacy studies. TRIAL REGISTRATION: ClinicalTrials.gov (NCT01261130 for the Brazil trial and NCT01385189 for the US trial).
[Mh] Termos MeSH primário: Ancylostomatoidea/imunologia
Antígenos de Helmintos/imunologia
Glutationa Transferase/imunologia
Infecções por Uncinaria/prevenção & controle
Vacinas Sintéticas/imunologia
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos/administração & dosagem
Adolescente
Adulto
Hidróxido de Alumínio/administração & dosagem
Animais
Anticorpos Anti-Helmínticos/sangue
Brasil
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/patologia
Feminino
Glucosídeos/administração & dosagem
Voluntários Saudáveis
Vacinas contra Hepatite B/administração & dosagem
Infecções por Uncinaria/imunologia
Seres Humanos
Imunoglobulina G/sangue
Injeções Intramusculares
Lipídeo A/administração & dosagem
Masculino
Meia-Idade
Resultado do Tratamento
Estados Unidos
Vacinas Sintéticas/administração & dosagem
Vacinas Sintéticas/efeitos adversos
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Antibodies, Helminth); 0 (Antigens, Helminth); 0 (Glucosides); 0 (Hepatitis B Vaccines); 0 (Immunoglobulin G); 0 (Lipid A); 0 (Vaccines, Synthetic); 0 (glucopyranosyl lipid-A); 5QB0T2IUN0 (Aluminum Hydroxide); EC 2.5.1.18 (Glutathione Transferase)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180129
[Lr] Data última revisão:
180129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pntd.0005574


  9 / 11534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29244936
[Au] Autor:Ignateva GA
[Ti] Título:Vaccine manufacturing and technology: from biotechnological platforms to syntethic epitopes, current viepoint.
[So] Source:Patol Fiziol Eksp Ter;60(4):143-7, 2016 Oct-Dec.
[Is] ISSN:0031-2991
[Cp] País de publicação:Russia (Federation)
[La] Idioma:eng
[Ab] Resumo:The Purposes: The Purposes: the review take into account short history of vaccination practice and development of vaccine technology. Methods: In the review we include data from several monographs about manufacturing of vaccines published by authors from such companies as Merck & Co; Sanofi Pasteur; Dynavax Europe/Rhein Biotech GmbH; Latham Biopharm Group; Aridis Pharmaceuticals LLC; Genentech; Amgen; Shamir Biologics LLC; Biopharm Services US; Novartis Pharma AG, аnd several research centers: Laboratory of Bacterial Polysaccharides, Center for Biologics Evaluation and Research; Purdue University, West Lafayette, IN, US; Department of Pharmaceutical Chemistry, Univ. Of Kansas; Max Planck Institute for dynamics of Complex Technical Systems; Fraunhofer USA Center for Molecular Biotechnology; US Dep. of Agriculture Animal and Plant Health Inspection Service, etc. Results: In historic literature there are data about inoculation practices in antique China, Persia, India, Byzantium, native Americans, some African population. In modern immunology since the end of XIX century the vaccines were produced at the in vivo platforms - in animals (rabbits, mice, cows). Since 1931 due to E. Goodpasture' elaboration most virus vaccines were and are produced at the in ovo platform. In 1949 J.F. Enders elaborated large-scale polio virus production in the primary culture of monkey kidney cells in vitro. Up to day primary culture of chiken embrio fibroblasts are used to large-scale production of vaccine viruses of measles, mumps, rabies. Since 2000-th in Western countries most part of virus vaccines were began to produced via a cultivation in continuous tumor cell lines. The last technology is the most low cost for large-scale production of vaccines. We review several new biotechnological platforms for the production of the recombinant protein or virus-like particles as subunit vaccines: plant system, algae, mushrooms, insect cells, etc. Conclusion: Beside of good purpose of vaccination - prophylactic of several infectious deseases, doctors must take into account possibility of inter-species transmission of unknown pathogens (retroviruses, prions, etc) from biotechnological platforms - animals, cell cultures - into human population, and don't ignore L.A. Zilber' theory of virus' etiology of cancer diseases.
[Mh] Termos MeSH primário: Biotecnologia/métodos
Epitopos
Vacinas Sintéticas
[Mh] Termos MeSH secundário: Animais
Epitopos/química
Epitopos/uso terapêutico
Seres Humanos
Vacinação
Vacinas Sintéticas/química
Vacinas Sintéticas/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Epitopes); 0 (Vaccines, Synthetic)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180118
[Lr] Data última revisão:
180118
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE


  10 / 11534 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457901
[Au] Autor:Haghighat S; Siadat SD; Rezayat Sorkhabadi SM; Akhavan Sepahi A; Sadat SM; Yazdi MH; Mahdavi M
[Ad] Endereço:Department of Microbiology, Faculty of Advanced Sciences and Technology, Pharmaceutical Sciences Branch, Islamic Azad University (IAUPS), Tehran, Iran. Electronic address: Haghighat.s@iaups.ac.ir.
[Ti] Título:Recombinant PBP2a as a vaccine candidate against methicillin-resistant Staphylococcus aureus: Immunogenicity and protectivity.
[So] Source:Microb Pathog;108:32-39, 2017 Jul.
[Is] ISSN:1096-1208
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Methicillin-resistant Staphylococcus aureus infections are focal and development of an effective vaccine can help to control this infection. Here, recombinant PBP2a was studied in mouse model. Following the preparation of recombinant PBP2a, Balb/c mice were injected subcutaneously with 20 µg of r-PBP2a formulated in Freund's adjuvant three times with three weeks intervals with proper control group. Total and specific isotype antibodies were evaluated on sera by ELISA. Opsonophagocytic activity was also investigated on the sera samples. Intraperitonealchallenge with a sub-lethal dose of MRSA (5 × 10 CFU) was done in experimental mice. Following that, the number of bacteria from kidneys of experimental mice were determined. Survival rate was recorded for 60 days. Significant increase of antibody with high level of IgG1, IgG2a and IgG2b isotypes was demonstrated in vaccinated mice versus the control group (P < 0.005). The bacterial load in the kidneys from immunized mice was 1000 times less thancontrol group (PBS) and opsonophagocytic activity of immunized mice sera significantly increased (P < 0.0001). Finally the life span of immunized mice after bacterial challenge was extended versus control mice. These results may indicate the capacity of PBP2a as a candidate vaccine to control the MRSA infections.
[Mh] Termos MeSH primário: Proteínas de Bactérias/genética
Proteínas de Bactérias/imunologia
Staphylococcus aureus Resistente à Meticilina/genética
Staphylococcus aureus Resistente à Meticilina/imunologia
Proteínas de Ligação às Penicilinas/genética
Proteínas de Ligação às Penicilinas/imunologia
Infecções Estafilocócicas/imunologia
Vacinas Antiestafilocócicas/genética
Vacinas Antiestafilocócicas/imunologia
Vacinas Sintéticas/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Anticorpos Antibacterianos/sangue
Antígenos de Bactérias/genética
Antígenos de Bactérias/imunologia
Carga Bacteriana
Clonagem Molecular
Modelos Animais de Doenças
Ensaio de Imunoadsorção Enzimática
Feminino
Imunidade Humoral/imunologia
Imunoglobulina G/sangue
Isotipos de Imunoglobulinas/imunologia
Rim/efeitos dos fármacos
Rim/microbiologia
Camundongos
Camundongos Endogâmicos BALB C
Alinhamento de Sequência
Análise de Sequência
Infecções Estafilocócicas/microbiologia
Infecções Estafilocócicas/prevenção & controle
Taxa de Sobrevida
Vacinação
Vacinas Sintéticas/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Bacterial); 0 (Antigens, Bacterial); 0 (Bacterial Proteins); 0 (Immunoglobulin G); 0 (Immunoglobulin Isotypes); 0 (Penicillin-Binding Proteins); 0 (Staphylococcal Vaccines); 0 (Vaccines, Synthetic); 0 (mecA protein, Staphylococcus aureus)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE



página 1 de 1154 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde